INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Molina Healthcare, Inc. - MOH

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Molina Healthcare, Inc. and its officers or directors [1] Financial Performance - On July 7, 2025, Molina reported preliminary adjusted earnings of approximately $5.50 per share and lowered its full-year 2025 adjusted earnings guidance by over 10% to a range of $21.50 to $22.50 per share [3] - Following this announcement, Molina's stock price decreased by $6.97 per share, approximately 2.9%, closing at $232.61 per share [3] - On July 23, 2025, Molina released finalized second-quarter results, reporting adjusted earnings per diluted share of $5.48, which missed both analyst consensus estimates and prior company guidance [4] - The earnings shortfall was attributed to elevated medical cost pressures, including increased utilization of behavioral health, pharmacy, and inpatient/outpatient services [4] - Molina again lowered its full-year guidance due to updated information and revised assumptions regarding medical cost trends [4] - Following this news, Molina's stock price fell by $32.03 per share, approximately 16.8%, closing at $158.22 per share [5]